Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC
|
|
- Randall Parks
- 5 years ago
- Views:
Transcription
1 CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride in Child Outpatients with Attention-Deficit/Hyperactivity Disorder Date summary approved by Lilly: 02 August 2007 Brief Summary of Results The primary objective of this study was to investigate the efficacy of atomoxetine treatment in reducing the severity of attention-deficit/hyperactivity disorder (ADHD) symptoms in Japanese pediatric and adolescent outpatients (6-17 years of age) by testing 3 fixed-dose ranges of atomoxetine (1.8 mg/kg/day, 1.2 mg/kg/day, 0.5 mg/kg/day) compared sequentially with placebo. The main instrument used to assess efficacy was the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Japanese Version (ADHD RS-IV-J) (DuPaul et al. 1998; Yamazaki et al. 2001), an 18-item scale with 1 item for each of the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD (APA 1994). This scale when used by investigators was designated as the ADHD RS-IV-J:I rating scale. The same scale was also used by the patients' teachers to assess symptoms in the classroom setting; this was designated as the ADHD RS-IV-J:School rating scale. The clinician assessment Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-AD/HD-S) was used as another measure of efficacy (Guy 1976; NIMH 1985). The primary efficacy variable used to evaluate atomoxetine treatment was ADHD RS-IV- J:I/School (Sch) total score, a comprehensive assessment in which the primary efficacy measure, the ADHD RS-IV-J:I rating scale, was administered and scored by the investigator in conjunction with teacher scores on the ADHD RS-IV-J:School rating scale. The ADHD RS-IV-J:I total score, ADHD RS-IV-J:School total score and CGI- ADHD-S assessment were used as secondary efficacy variables. Secondary objectives included comparing the efficacy of each of the above 3-fixed atomoxetine dose ranges with one another and with placebo, comparing the safety of
2 CT Registry ID# 5285 Page 2 these 3 dose ranges with that of placebo, and evaluating the plasma concentration of atomoxetine and its main metabolites with respect to dose and patient ability to metabolize atomoxetine based on their CYP2D6 genotype (i.e., EM: Extensive metabolizers, IM: Intermediate metabolizers, PM: Poor metabolizers). The main results of this study were as follows: 1.8 mg/kg/day was shown to be statistically significant compared with placebo in ameliorating ADHD symptoms in Japanese pediatric ADHD patients (ADHD RS-IV-J:I/Sch total score: p=0.010/one-sided; ADHD RS-IV-J:I total score: p=0.008/one-sided). The low 0.5 mg/kg/day dose and intermediate 1.2 mg/kg/day dose were not found to be statistically significant in ameliorating ADHD symptoms compared with placebo. A statistically significant linear dose response in efficacy was seen with increasing atomoxetine dose (ADHD RS-IV-J:I/Sch total score: p=0.008; ADHD RS-IV-J:I total score: p=0.007; ADHD RS-IV- J:School total score: p=0.026). Measurement of the secondary efficacy variables ADHD RS-IV- J:School total score and CGI-ADHD-S assessment did not show any statistically significant difference between atomoxetine treatment and placebo. Analysis of laboratory analytes did not reveal any pattern of abnormalities associated with atomoxetine administration. No deaths occurred during this study. Two patients discontinued the study due to adverse events. One SAE was reported during the course of the study: hospitalization (twice) due to vomiting and headache. This patient recovered and completed the study. The most commonly reported treatment-emergent adverse events (TEAEs; 10%) in all atomoxetine treatment groups were nasopharyngitis (15.8% : 29/183), headache (14.2% : 26/183), and decreased appetite (12% : 22/183). Two adverse events above the 5% level in patients given atomoxetine were statistically significant: decreased appetite in 12% (22/183 : p<0.001) and vomiting in 8.2% (15/183 : p=0.022). Statistically significant (p<0.05) increases in mean diastolic blood pressure and heart rate (pulse) were observed at all atomoxetine doses. A statistically significant dose response (p<0.001) was also observed for diastolic blood pressure and heart rate.
3 CT Registry ID# 5285 Page 3 No statistically significant increases in mean QTc interval (Fridericia, Data Driven corrections) were found for any of the atomoxetine treatment groups. All mean increases seen with these two corrections were below 5 msec. Neither the Fridericia nor the Data Driven correction gave any evidence of an atomoxetine linear dose response in QTc mean change. Analysis of categorical changes in QTc interval (Fridericia, Data Driven corrections) detected statistically significant trends in QTc prolongation 30 msec in 15 (8.2%) patients (Fridericia: p=0.015) and 16 (8.7%) patients (Driven Driven: p=0.034) from the atomoxetine treatment groups. However, there were no prolongation times longer than 450 msec, and none longer than 60 msec. There were no adverse events or study discontinuations related to QTc interval prolongation. There were no study discontinuations and no evidence of differences in tolerability among patients with decreased efficiency to metabolize atomoxetine (IM and PM patients with respect to CYP2D6 genotype). Title of Study: Investigator(s): A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride in Child Outpatients with Attention-Deficit/Hyperactivity Disorder This multicenter study included 41 principal investigators. Study Center(s): This study was conducted at 41 study centers in one country. Length of Study: 1 year 7 months Date first patient enrolled: 22 February 2005 Date last patient completed: 29 September 2006 Phase of Development: 2/3 Objectives: Primary objective: To test the efficacy of atomoxetine treatment in reducing the severity of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Japanese children and adolescents who were at least 6 years of age but less than 18 years of age by testing 1.8, 1.2, and 0.5 mg/kg/day doses of atomoxetine compared sequentially with placebo as measured by the ADHD RS-IV-J:I/Sch total score. Secondary objectives: (1)To compare the safety of 3 fixed-dose ranges of atomoxetine with that of placebo. (2)To assess the relationship between atomoxetine dose and both efficacy and safety. (3)To compare the efficacy of each of 3 fixed doses of atomoxetine with one another and with placebo in children who have not had prior treatment with psychostimulants. (4)To evaluate the plasma concentration of atomoxetine, 4-hydroxyatomoxetine, and N-desmethylatomoxetine with respect to dose and cytochrome P450 2D6 (CYP2D6) metabolic status.
4 CT Registry ID# 5285 Page 4 (5)To evaluate during the course of the study the teacher s assessment as measured by ADHD RS-IV-J:School total score. Study Design: Randomized, double blind, placebo-controlled study (Figure LYBC.1) Number of Patients: Planned: per treatment group (4 groups): placebo atomoxetine 0.5 mg/kg/day atomoxetine 1.2 mg/kg/day atomoxetine 1.8 mg/kg/day Randomized: 245 placebo 62 atomoxetine 0.5 mg/kg/day: 62 atomoxetine 1.2 mg/kg/day: 60 atomoxetine 1.8 mg/kg/day: 61 Completed: 234 placebo: 61 (173: atomoxetine) atomoxetine 0.5 mg/kg/day: 60 atomoxetine 1.2 mg/kg/day: 57 atomoxetine 1.8 mg/kg/day: 56 Diagnosis and Main Criteria for Inclusion: Japanese male and female patients who were at least 6 but less than 18 years of age and who met the criteria for ADHD found in the Diagnostic and Statistical Manual of Mental Disorders (APA 1994) and in the Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version: Behavioral Disorders Supplement (K-SADS-PL: Behavioral) module (Kaufman et al. 1997). Study Drug, Dose, and Mode of Administration: hydrochloride 4 capsule sizes : 2.5 mg, 5 mg, 10 mg, 20 mg Combination of capsules given orally twice a day to provide target daily dosage based on patient body weight. Reference Therapy, Dose, and Mode of Administration: Placebo: Identical in appearance and administration to study drug. Duration of Treatment: 56 days (planned) days (allowed) Variables: Efficacy: Primary: ADHD RS-IV-J:I/Sch total score Secondary: ADHD RS-IV-J:I total score ADHD RS-IV-J:School total score CGI-AD/HD-S (clinician assessment) Safety: Adverse events, clinical laboratory tests, vital signs, electrocardiograms Pharmacokinetic: Concentrations (atomoxetine and its metabolites: 4-hydroxyatomoxetine, and N- desmethylatomoxetine)
5 CT Registry ID# 5285 Page 5 Evaluation Methods: Statistical: The primary efficacy variable was the change from baseline to last observation carried forward (LOCF) endpoint in the ADHD RS-IV-J:I/Sch total score. ADHD RS-IV-J:I/Sch was defined as the ADHD RS-IV-J:I total score assessed in conjunction with the ADHD RS-IV-J:School total score collected at the same time for a specific visit. For the primary efficacy analysis the Williams test was performed to compare sequentially 1.8 mg/kg/day, 1.2 mg/kg/day, and 0.5 mg/kg/day doses of atomoxetine with placebo in order to determine the minimum effective dose. Statistical significance was p<0.025 (one-sided William's test). Statistical significance in all other tests was two-sided, p<0.05. Pharmacokinetic: Blood samples taken with a sparse sampling approach were evaluated by population pharmacokinetics to characterize the pharmacokinetics of atomoxetine, 4-hydroxyatomoxetine, and N-desmethylatomoxetine. Plasma atomoxetine concentrations together with patient characteristics were evaluated using the nonlinear mixed effects modeling program (NONMEM) and graphical analyses. Pharmacokinetics of 4-hydroxyatomoxetine and N- desmethylatomoxetine were evaluated using graphical methods only. Results: Study Design Study LYBC comprised two study periods (Figure LYBC.1): Study Period I: Screening, Medication Washout, and Assessment Study Period II: Randomized, Double-Blind Acute Treatment Patients who met entry criteria completed an initial washout, screening, and assessment period of days (Study Period I). This was then followed by approximately 8 weeks of acute treatment (Study Period II). At the end of this period dosages were abruptly discontinued.
6 CT Registry ID# 5285 Page 6 Study Period I Screening, Washout, and Assessment Study Period II Double-Blind Acute Treatment Dose titration 0.8 mg/kg/day 1.8 mg/kg/day 1.2 mg/kg/day 0.5 mg/kg/day Placebo Suggested Interval Between Visits (Days) 14 (12-35 allowed) 14 (12-18 allowed) 14 (12-18 allowed) 14 (12-21 allowed) 14 (12-21 allowed) Visit Figure LYBC.1. Study design. Patient Demographics Table LYBC.1 shows patient demographics at baseline for the 243 patients in the Full Analysis Set (FAS: see section on Efficacy). All of the treatment groups were balanced with respect to patient demographics with no major imbalances among treatment groups for any characteristic. Patients ranged from 6 to 17 years of age (mean: years). There were 155 (85.6%) males and 26 (14.4%) females in the atomoxetine treatment groups, and of these 181 patients, 100 (55.2%) had prior stimulant use. Two (1.1%) of the patients in the atomoxetine treatment groups were classified as poor metabolizers (PM) with respect to CYP2D6 genotype: 1 patient in the low dose group (atomoxetine 0.5 mg/kg/day) and 1 in the intermediate dose group (atomoxetine 1.2 mg/kg/day). With regards to ADHD subtype, 61.3% (149/243) of the patients were Inattentive, 4.5% (11/243) Hyperactive/Impulsive, and 34.2% (83/243) Mixed. The severity of disease at baseline for all patients in the Full Analysis Set is summarized in Table LYBC.2. All of the treatment groups were well balanced for each measure of disease severity. No statistically significant difference between groups in mean baseline score was seen for any measure. In order to better understand the effect of CYP2D6 genotype on the metabolism, efficacy, and safety of atomoxetine, two IM (intermediate metabolizer) patient categories (Category 1, Category 2) based on CYP2D6 allele type were defined as subsets of the EM (extensive metabolizer) patients. The number of EM, IM, and PM patients in each treatment group for the Full Analysis Set is shown in Table LYBC.3 by metabolizer type.
7 CT Registry ID# 5285 Page 7 No statistically significant difference was observed between treatment groups with respect to the number of EM / IM / PM patients in each group.
8 Table LYBC.1. Patient Demographic Characteristics at Baseline Full Analysis Set Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all All p-value (N=62) (N=62) (N=59) (N=60) (N=181) (N=243) Gender Male 52( 83.9) 52( 83.9) 51( 86.4) 52( 86.7) 155( 85.6) 207( 85.2) * Female 10( 16.1) 10( 16.1) 8( 13.6) 8( 13.3) 26( 14.4) 36( 14.8) Origin EastAsian 62(100.0) 62(100.0) 59(100.0) 60(100.0) 181(100.0) 243(100.0) - Age No.patients ** Mean SD Min Median Max Age:Yrs 6 0( 0.0) 3( 4.8) 2( 3.4) 3( 5.0) 8( 4.4) 8( 3.3) - 7 5( 8.1) 9( 14.5) 9( 15.3) 10( 16.7) 28( 15.5) 33( 13.6) 8 10( 16.1) 11( 17.7) 8( 13.6) 6( 10.0) 25( 13.8) 35( 14.4) 9 8( 12.9) 14( 22.6) 11( 18.6) 5( 8.3) 30( 16.6) 38( 15.6) 10 13( 21.0) 3( 4.8) 9( 15.3) 7( 11.7) 19( 10.5) 32( 13.2) 11 8( 12.9) 8( 12.9) 3( 5.1) 13( 21.7) 24( 13.3) 32( 13.2) 12 8( 12.9) 4( 6.5) 7( 11.9) 6( 10.0) 17( 9.4) 25( 10.3) 13 7( 11.3) 2( 3.2) 3( 5.1) 4( 6.7) 9( 5.0) 16( 6.6) 14 2( 3.2) 3( 4.8) 3( 5.1) 2( 3.3) 8( 4.4) 10( 4.1) 15 1( 1.6) 3( 4.8) 0( 0.0) 1( 1.7) 4( 2.2) 5( 2.1) 16 0( 0.0) 2( 3.2) 1( 1.7) 2( 3.3) 5( 2.8) 5( 2.1) 17 0( 0.0) 0( 0.0) 3( 5.1) 1( 1.7) 4( 2.2) 4( 1.6) CYP2D6 EM 62(100.0) 61( 98.4) 58( 98.3) 60(100.0) 179( 98.9) 241( 99.2) ** Genotype PM 0( 0.0) 1( 1.6) 1( 1.7) 0( 0.0) 2( 1.1) 2( 0.8) CT Registry ID# 5285 Page 8
9 Table LYBC.1. Patient Demographic Characteristics at Baseline Full Analysis Set (Concluded) Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all All p-value (N=62) (N=62) (N=59) (N=60) (N=181) (N=243) AD/HD Inattentive 37( 59.7) 38( 61.3) 35( 59.3) 39( 65.0) 112( 61.9) 149( 61.3) ** Subtype Hyp/Imp 1( 1.6) 3( 4.8) 4( 6.8) 3( 5.0) 10( 5.5) 11( 4.5) Mixed 24( 38.7) 21( 33.9) 20( 33.9) 18( 30.0) 59( 32.6) 83( 34.2) Prior Yes 32( 51.6) 34( 54.8) 33( 55.9) 33( 55.0) 100( 55.2) 132( 54.3) * Stimulant No 30( 48.4) 28( 45.2) 26( 44.1) 27( 45.0) 81( 44.8) 111( 45.7) Exposure V1 Height No.patients ** Mean SD Min Median Max V1 Weight No.patients ** Mean SD Min Median Max WISC-III No.patients ** Mean SD Min Median Max *Frequencies are analyzed using Fisher Exact test. **Means are analyzed using a Type III Sum of Square Analysis of Variance. Abbreviations: AD/HD = attention deficit/hyperactivity disorder; ATMX = atomoxetine; EM = extensive metabolizer; Hyp/Imp = hyperactive/impulsive; Max = maximum; min = minimum; N = total number of patients; No = number; PM = poor metabolizer; SD = standard deviation; V = visit; WISC-III = Wechsler Intelligence Scale for Children-III; Yrs = years. CT Registry ID# 5285 Page 9
10 Table LYBC.2. Severity of Disease at Baseline Full Analysis Set Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all All p-value* (N=62) (N=62) (N=59) (N=60) (N=181) (N=243) Baseline No. Patients ADHD RS-IV-J:I/Sch Mean Total score SD Min Median Max Baseline No. Patients ADHD RS-IV-J:I Mean Total score SD Min Median Max Baseline No. Patients ADHD RS-IV-J:School Mean Total score SD Min Median Max Baseline No. Patients CGI-AD/HD-S Mean SD Min Median Max *Means are analyzed using a Type III Sum of Square Analysis of Variance. Abbreviations: ADHD RS-IV-J:I/Sch = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored/School; ATMX = atomoxetine; CGI-AD/HD-S = Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity; Max = maximum; min = minimum; N = total number of patients; No = number; SD = standard deviation. CT Registry ID# 5285 Page 10
11 Table LYBC.3. CYP2D6 (EM/IM/PM) at Baseline Full Analysis Set Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all All p-value (N=62) (N=62) (N=59) (N=60) (N=181) (N=243) CYP2D6 EM 51( 82.3) 46( 74.2) 44( 74.6) 49( 81.7) 139( 76.8) 190( 78.2) * EM/IM/PM IM 11( 17.7) 15( 24.2) 14( 23.7) 11( 18.3) 40( 22.1) 51( 21.0) Category 1 PM 0( 0.0) 1( 1.6) 1( 1.7) 0( 0.0) 2( 1.1) 2( 0.8) CYP2D6 EM 46( 74.2) 42( 67.7) 40( 67.8) 46( 76.7) 128( 70.7) 174( 71.6) * EM/IM/PM IM 16( 25.8) 19( 30.6) 18( 30.5) 14( 23.3) 51( 28.2) 67( 27.6) Category 2 PM 0( 0.0) 1( 1.6) 1( 1.7) 0( 0.0) 2( 1.1) 2( 0.8) *Frequencies are analyzed using Fisher Exact test. Abbreviations: ATMX = atomoxetine; EM = extensive metabolizer; IM = intermediate metabolizer; N = total number of patients; PM = poor metabolizer. CT Registry ID# 5285 Page 11
12 CT Registry ID# 5285 Page 12 Patient Disposition An overview of patient disposition is shown in Figure LYBC.2. Patients Entered N=270 Patients Randomized N=245 Screen Failure: N=25 Reason: Entry Criteria Exclusion 23 Protocol Violation 1 Patient Decision 1 Placebo N=62 ATMX 0.5 N=62 ATMX 1.2 N=60 ATMX 1.8 N=61 Discontinuation N=1 Reason: Sponsor Decision 1 Discontinuation N=2 Reason: Lack of Efficacy 1 Protocol Violation 1 Discontinuation N=3 Reason: Adverse Event 1 Protocol Violation 1 Patient Decision 1 Discontinuation N=5 Reason: Protocol Violation 2 Adverse Event 1 Entry Criteria Exclusion 1 Physician Decision 1 Study Completed N=61 Study Completed N=60 Study Completed N=57 Study Completed N=56 Figure LYBC.2. Abbreviations: ATMX = atomoxetine; N = total number of patients. Patient disposition. Of the 270 patients who entered the study, 25 failed the initial screening procedures and were discontinued prior to randomization. Table LYBC.4 shows the percentage of enrolled patients who discontinued from Study Period II for specific reasons. Of the 245 randomized patients, 11 (4.5%) discontinued the study. The single patient who discontinued for lack of efficacy was in the low dose treatment group (atomoxetine 0.5 mg/kg/day). Two patients (0.8%) discontinued the study because of adverse events. Of the 183 patients in the three atomoxetine treatment groups, 173 (94.5%) completed Study Period II. In the placebo treatment group 61 (98.4%) patients completed Study Period II.
13 Table LYBC.4. Primary Reason for Study Discontinuation All Randomized Patients Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all Reason for Discontinuation (N=62) (N=62) (N=60) (N=61) (N=183) p-value* n (%) n (%) n (%) n (%) n (%) Patients Completed 61 (98.4) 60 (96.8) 57 (95.0) 56 (91.8) 173 (94.5) Adverse event 0 ( 0.0) 0 ( 0.0) 1 ( 1.7) 1 ( 1.6) 2 ( 1.1) Death 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) Lost to Follow up 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) Protocol entry exclusion 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 1 ( 1.6) 1 ( 0.5) Protocol violation 0 ( 0.0) 1 ( 1.6) 1 ( 1.7) 2 ( 3.3) 4 ( 2.2) Patient decision/parent decision 0 ( 0.0) 0 ( 0.0) 1 ( 1.7) 0 ( 0.0) 1 ( 0.5) Physician decision 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 1 ( 1.6) 1 ( 0.5) Sponsor decision 1 ( 1.6) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) 0 ( 0.0) Lack of efficacy 0 ( 0.0) 1 ( 1.6) 0 ( 0.0) 0 ( 0.0) 1 ( 0.5) * P-value derived from Fisher Exact test Abbreviations: ATMX = atomoxetine; N = total number of patients. CT Registry ID# 5285 Page 13
14 CT Registry ID# 5285 Page 14 Efficacy Datasets analyzed for efficacy are shown in Figure LYBC.3. All efficacy analyses were performed for patients who met the study inclusion criteria, took at least one dose of the study medication, and had a baseline and post-baseline measurement. This set of patients was designated as the Full Analysis Set (FAS). All randomized patients (245) met the study inclusion criteria, took at least one dose of the study medication (placebo or atomoxetine), and had a baseline and post-baseline measurement. Two of these patients took prohibited drugs prior to the first visit after randomization and were excluded from the efficacy analysis. Thus, 243 patients were included in the efficacy analysis. These patients comprised the Full Analysis Set. Only ADHD RS-IV-J:I scores that were used to assess patients in conjunction with teacher scores on the ADHD RS-IV-J:School rating scale were included in the primary efficacy analysis. These were designated as ADHD RS-IV-J:I/Sch scores, and only patients with these scores for Visit 2 and at least their final visit (Visit 6, or prior visit LOCF) were included in the ADHD RS-IV-J:I/Sch data set. Two of the 243 patients included in the Full Analysis Set lacked either baseline or post-baseline scores on the ADHD RS-IV-J:School rating scale and were thus excluded from the ADHD RS-IV- J:I/Sch data set. Therefore, 241 patients were included in the primary efficacy analysis (ADHD RS-IV-J:I/Sch data set).
15 CT Registry ID# 5285 Page 15 All Randomized Patients Placebo 62 ATMX ATMX ATMX Patients who took at least 1 dose of study medication Placebo 62 ATMX ATMX ATMX Full Analysis Set Placebo 62 ATMX ATMX ATMX Patients who took no study medication Placebo 0 ATMX ATMX ATMX Patients Excluded Placebo 0 ATMX ATMX ATMX ADHD RS-IV-J:I/Sch Placebo 61 ATMX ATMX ATMX ADHD RS-IV-J:I Placebo 62 ATMX ATMX ATMX ADHD RS-IV-J:School Placebo 61 ATMX ATMX ATMX CGI-AD/HD-S Placebo 62 ATMX ATMX ATMX Abbreviations: ADHD RS-IV-J:I/Sch = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV- Parent Version: Investigator-Administered and Scored/School; ATMX = atomoxetine; CGI- AD/HD-S = Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity. Figure LYBC.3. Patients included in the efficacy analyses. Primary Outcome Measure The primary efficacy variable was the ADHD RS-IV-J:I/Sch total score. Table LYBC.5 contains the mean baseline, endpoint (LOCF), and change from baseline to endpoint in mean ADHD RS-IV-J:I/Sch total score. 1.8 mg/kg/day showed a statistically significant overall improvement in mean change of ADHD RS-IV- J:I/Sch total score from baseline to endpoint (-11.6: SD=8.8, p=0.010/one-sided) compared with placebo. There was no statistically significant difference between atomoxetine 1.2 mg/kg/day and placebo. However, decreases from baseline in mean
16 CT Registry ID# 5285 Page 16 ADHD RS-IV-J:I/Sch total score did show a statistically significant linear response with increasing atomoxetine dose (p=0.008).
17 Table LYBC.5. ADHD RS-IV-J:I/Sch Change from Baseline to LOCF Endpoint Full Analysis Set Baseline Endpoint Change 95%CI** P-value* P-value** n Mean SD Mean SD Mean SD Diff** LCL UCL Williams ANCOVA ADHD RS-IV-J:I/Sch : Total score Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:I/Sch : Inattentive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:I/Sch : Hyperactive/Impulsive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = N:number of patients who are included in Full Analysis Set. * P-value(One sided) is derived from Williams test. ** Unadjusted p-value, treatment difference, the confidence interval is derived from pairwise treatment comparison vs Placebo using ANCOVA model. *** Dose Response p-value is derived from then contrasts of the least-square means from ANCOVA model. ANCOVA model: change = baseline + treatment Linear Contrast: , Quadratic Contrast: Abbreviations: ADHD RS-IV-J:I/Sch = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator- Administered and Scored/School; ANCOVA = analysis of covariance; ATMX = atomoxetine; CI = confidence interval; Diff = difference; LCL = lower control limit; n = number of patients; SD = standard deviation; UCL = upper control limit. CT Registry ID# 5285 Page 17
18 CT Registry ID# 5285 Page 18 Figure LYBC.4 shows the mean reduction from baseline to endpoint in ADHD RS-IV- J:I/Sch total score for all treatment groups. The reduction in both the atomoxetine 1.2 mg/kg/day and 1.8 mg/kg/day groups was larger than that of placebo; however only those reductions observed in the 1.8 mg/kg/day group were statistically significant (p<0.025/one-sided). * Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ATMX = atomoxetine. * p< Figure LYBC.4. Mean reduction from baseline to endpoint in ADHD RS-IV- J:I/Sch Total Scores for all atomoxetine treatment groups in the full analysis set. Secondary Outcome Measures The principal secondary efficacy variables were: ADHD RS-IV-J:I total score ADHD RS-IV-J:School total score CGI-AD/HD-S clinician assessment.
19 CT Registry ID# 5285 Page 19 In order to better understand the effect of atomoxetine on inattention symptoms compared with hyperactivity-impulsivity symptoms, the following subscale scale scores were also used as secondary efficacy variables: ADHD RS-IV-J:I/Sch Inattentive subscale score ADHD RS-IV-J:I/Sch Hyperactive/Impulsive subscale score ADHD RS-IV-J:I Inattentive subscale score ADHD RS-IV-J:I Hyperactive/Impulsive subscale score ADHD RS-IV-J:School Inattentive subscale score ADHD RS-IV-J:School Hyperactive/Impulsive subscale score The 18-item ADHD RS-IV-J:I rating scale is designed such that odd-numbered items focus on inattention symptoms and even-numbered items on hyperactivity-impulsive symptoms. Total scores for these specific subsets were used for the above subscale scores. The following results were obtained for secondary measure outcomes: A statistically significant decrease from baseline in mean ADHD RS-IV-J:I/Sch Inattentive subscale score (p=0.019/one-sided) compared with placebo was seen in the atomoxetine 1.8 mg/kg/day group (Table LYBC.5). Statistically significant decreases from baseline in both mean ADHD RS-IV-J:I total score (p=0.008/one-sided) and mean ADHD RS-IV-J:I Inattentive subscale score (p=0.016/one-sided) compared with placebo were seen in the atomoxetine 1.8 mg/kg/day group (Table LYBC.6). A statistically significant (p 0.05) linear dose response with increasing atomoxetine dose was observed for all secondary measure outcomes with the exception of ADHD RS-IV-J:School Hyperactive/Impulsive subscale score and CGI-AD/HD-S clinician assessment (Tables LYBC.5~8). No statistically significant differences from baseline were seen in mean ADHD RS-IV-J:School total score, nor were any seen in mean ADHD RS-IV-J:School Inattentive or Hyperactive/Impulsive subscale scores compared with placebo (Table LYBC.7). No statistically significant differences were seen in mean CGI-AD/HD-S change from baseline (Table LYBC.8).
20 Table LYBC.6. ADHD RS-IV-J:I Change from Baseline to LOCF Endpoint Full Analysis Set Baseline Endpoint Change 95%CI** P-value* P-value** n Mean SD Mean SD Mean SD Diff** LCL UCL Williams ANCOVA ADHD RS-IV-J:I: Total score Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:I: Inattentive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:I: Hyperactive/Impulsive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = N:number of patients who are included in Full Analysis Set. * P-value(One sided) is derived from Williams test. ** Unadjusted p-value, treatment difference, the confidence interval is derived from pairwise treatment comparison vs Placebo using ANCOVA model. *** Dose Response p-value is derived from then contrasts of the least-square means from ANCOVA model. ANCOVA model: change = baseline + treatment Linear Contrast: , Quadratic Contrast: Abbreviations: ADHD RS-IV-J:I = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored; ANCOVA = analysis of covariance; ATMX = atomoxetine; CI = confidence interval; Diff = difference; LCL = lower control limit; n = number of patients; SD = standard deviation; UCL = upper control limit. CT Registry ID# 5285 Page 20
21 Table LYBC.7. ADHD RS-IV-J:School Change from Baseline to LOCF Endpoint Full Analysis Set Baseline Endpoint Change 95%CI** P-value* P-value** n Mean SD Mean SD Mean SD Diff** LCL UCL Williams ANCOVA ADHD RS-IV-J:School: Total score Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:School: Inattentive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = ADHD RS-IV-J:School: Hyperactive/Impulsive Subscale Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = N:number of patients who are included in Full Analysis Set. * P-value(One sided) is derived from Williams test. ** Unadjusted p-value, treatment difference, the confidence interval is derived from pairwise treatment comparison vs Placebo using ANCOVA model. *** Dose Response p-value is derived from then contrasts of the least-square means from ANCOVA model. ANCOVA model: change = baseline + treatment Linear Contrast: , Quadratic Contrast: Abbreviations: ADHD RS-IV-J:School = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: School; ANCOVA = analysis of covariance; ATMX = atomoxetine; CI = confidence interval; Diff = difference; LCL = lower control limit; n = number of patients; SD = standard deviation; UCL = upper control limit. CT Registry ID# 5285 Page 21
22 Table LYBC.8. CGI-AD/HD-S Change from Baseline to LOCF Endpoint Full Analysis Set Baseline Endpoint Change 95%CI** P-value* P-value** n Mean SD Mean SD Mean SD Diff** LCL UCL Williams ANCOVA CGI-AD/HD-S Placebo ATMX ATMX ATMX Dose Response *** Linear: P = Quadratic: P = N:number of patients who are included in Full Analysis Set. * P-value(One sided) is derived from Williams test. ** Unadjusted p-value, treatment difference, the confidence interval is derived from pairwise treatment comparison vs Placebo using ANCOVA model. *** Dose Response p-value is derived from then contrasts of the least-square means from ANCOVA model. ANCOVA model: change = baseline + treatment Linear Contrast: , Quadratic Contrast: Abbreviations: ANCOVA = analysis of covariance; ATMX = atomoxetine; CGI-AD/HD-S = Clinical Global Impressions-Attention- Deficit/Hyperactivity Disorder-Severity; CI = confidence interval; Diff = difference; LCL = lower control limit; n = number of patients; SD = standard deviation; UCL = upper control limit. CT Registry ID# 5285 Page 22
23 CT Registry ID# 5285 Page 23 Safety Of the 245 patients who entered this study, 183 received at least one dose of atomoxetine. There were no patient deaths. One SAE was reported: hospitalization (twice) due to headache and vomiting. Two patients discontinued the study because of adverse events (affect lability and headache). Treatment-Emergent Adverse Events TEAEs were those adverse events that emerged or deteriorated during the study drug administration period. Table LYBC.9 summarizes TEAEs that occurred in at least 5% of patients who took at least one dose of study medication (placebo or atomoxetine). At least one TEAE was reported for 78.7% (144/183) of the patients given atomoxetine. The most commonly reported events ( 10%) in all atomoxetine treatment groups were nasopharyngitis, headache, and decreased appetite. Two adverse events above the 5% level were found to have a statistically significant (p<0.05) relationship to dose: decreased appetite in 12% (22/183 : p<0.001) and vomiting in 8.2% (15/183 : p=0.022) of patients given atomoxetine. Treatment-Emergent Adverse Drug Reactions (ADRs) ADRs were those TEAEs indicated by the investigator to be related or possibly related to atomoxetine administration. Table LYBC.10 summarizes ADRs that occurred in at least 5% of patients who took at least one dose of study medication. At least one ADR was reported for 50.3% (92/183) of the patients given atomoxetine. In these patients the ADR incidence rate was found to have a statistically significant relationship (p=0.003) with increasing atomoxetine dose. The most commonly reported ADRs ( 10%) were decreased appetite and headache. Decreased appetite in 11.5% (21/183) of the atomoxetine-treated patients was found to have a statistically significant (p<0.001) dose response.
24 Table LYBC.9. Treatment-Emergent Adverse Events Experienced By at Least 5% of Patients - MedDRA preferred Term Patients Who Took at Least 1 Dose of Study Medication Event Classification Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all p-value (N=62) (N=62) (N=60) (N=61) (N=183) CA Trend N (%) N (%) N (%) N (%) N (%) Test* Patient with>=1 TEAE 43 ( 69.4) 49 ( 79.0) 47 ( 78.3) 48 ( 78.7) 144 ( 78.7) Patient without TEAE 19 ( 30.6) 13 ( 21.0) 13 ( 21.7) 13 ( 21.3) 39 ( 21.3) Nasopharyngitis 10 ( 16.1) 11 ( 17.7) 7 ( 11.7) 11 ( 18.0) 29 ( 15.8) Headache 4 ( 6.5) 7 ( 11.3) 10 ( 16.7) 9 ( 14.8) 26 ( 14.2) Decreased appetite 2 ( 3.2) 3 ( 4.8) 6 ( 10.0) 13 ( 21.3) 22 ( 12.0) <0.001 Somnolence 4 ( 6.5) 4 ( 6.5) 6 ( 10.0) 8 ( 13.1) 18 ( 9.8) Nausea 3 ( 4.8) 4 ( 6.5) 6 ( 10.0) 6 ( 9.8) 16 ( 8.7) Vomiting 0 ( 0.0) 3 ( 4.8) 7 ( 11.7) 5 ( 8.2) 15 ( 8.2) Abdominal pain 5 ( 8.1) 5 ( 8.1) 4 ( 6.7) 2 ( 3.3) 11 ( 6.0) Diarrhoea 2 ( 3.2) 1 ( 1.6) 6 ( 10.0) 4 ( 6.6) 11 ( 6.0) *P-value is derived from Cochran Armitage Trend test. MedDRA Version 9.1 Abbreviations: ATMX = atomoxetine; N = number of patients; TEAE = treatment-emergent adverse event. CT Registry ID# 5285 Page 24
25 Table LYBC.10. Treatment-Emergent Adverse Drug Reactions Experienced By at Least 5% of Patients - MedDRA preferred Term Patients Who Took at Least 1 Dose of Study Medication Event Classification Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all p-value (N=62) (N=62) (N=60) (N=61) (N=183) CA Trend N (%) N (%) N (%) N (%) N (%) Test* Patient with>=1 ADR 19 ( 30.6) 25 ( 40.3) 35 ( 58.3) 32 ( 52.5) 92 ( 50.3) Patient without ADR 43 ( 69.4) 37 ( 59.7) 25 ( 41.7) 29 ( 47.5) 91 ( 49.7) Decreased appetite 2 ( 3.2) 3 ( 4.8) 6 ( 10.0) 12 ( 19.7) 21 ( 11.5) <0.001 Headache 3 ( 4.8) 5 ( 8.1) 8 ( 13.3) 8 ( 13.1) 21 ( 11.5) Somnolence 3 ( 4.8) 3 ( 4.8) 6 ( 10.0) 8 ( 13.1) 17 ( 9.3) Nausea 3 ( 4.8) 4 ( 6.5) 5 ( 8.3) 4 ( 6.6) 13 ( 7.1) *P-value is derived from Cochran Armitage Trend test. MedDRA Version 9.1 Abbreviations: ADR = adverse drug reaction; ATMX = atomoxetine; N = number of patients. CT Registry ID# 5285 Page 25
26 CT Registry ID# 5285 Page 26 Serious Adverse Events (SAEs) One SAE was reported during the course of the study: an 8-year old Japanese male randomized to the atomoxetine 1.8 mg/kg/day group was hospitalized twice due to headache and vomiting. The patient recovered from these events and completed the study. Study Discontinuations Due to Adverse Events Two patients discontinued the study because of adverse events: a 10-year-old Japanese male (atomoxetine 1.8 mg/kg/day group; affect lability), and a 14-year-old Japanese female (atomoxetine 1.2 mg/kg/day group; headache). Clinical Laboratory Values As determined by the Sponsor, analysis of laboratory analytes did not reveal any pattern of abnormalities associated with atomoxetine administration. Vital Signs Mean change from baseline to LOCF endpoint in vital sign measures are shown in Table LYBC.11. There were no study discontinuations related to changes in vital signs. A statistically significant (p<0.05) increase in mean diastolic blood pressure from baseline to endpoint was observed for all atomoxetine doses. The difference between treatment groups was statistically significant (p=0.003), and the dose-response was found to have a statistically significant (p<0.001) linear component. A statistically significant linear dose-response (p=0.029) was also observed for mean systolic blood pressure. No statistically significant difference was found between treatment groups. A statistically significant (p 0.001) increase was also observed in mean heart rate (pulse) for all atomoxetine doses. The difference between treatment groups was statistically significant (p<0.001) as was the linearity of the dose response (p<0.001). These results were not unexpected given the pharmacologic action of this drug. With regards to mean height, a statistically significant dose response was observed with the quadratic contrast from the ANCOVA model (p=0.036). However, there was no statistically significant difference between treatment groups. Changes in mean weight among treatment groups and the linearity of dose response were both statistically significant (p<0.001). When baseline and endpoint values were compared, statistically significant decreases in weight were seen for both the atomoxetine 1.2 mg/kg/day (p=0.002) and 1.8 mg/kg/day (p<0.001) groups. Dose response was also found to have a statistically significant (p<0.001) linear component.
27 Table LYBC.11. Vital Signs Mean Change from Baseline to LOCF Endpoint Patients Who Took at Least 1 Dose of Study Medication Baseline Endpoint Change p-value Therapy n Mean SD Mean SD Mean SD Within* Between** Systolic Placebo Blood Pressure ATMX ATMX ATMX Dose Response*** Linear: P=0.029 Quadratic: P=0.807 Diastolic Placebo Blood Pressure ATMX ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.388 Heart Rate(Pulse) Placebo <0.001 ATMX ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.181 Height Placebo < ATMX <0.001 ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=0.092 Quadratic: P=0.036 CT Registry ID# 5285 Page 27
28 Table LYBC.11. Vital Signs Mean Change from Baseline to LOCF Endpoint Patients Who Took at Least 1 Dose of Study Medication (Concluded) Baseline Endpoint Change p-value Therapy n Mean SD Mean SD Mean SD Within* Between** Weight Placebo <0.001 <0.001 ATMX ATMX ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.026 N: number of patients who took at least one dose of study medication * Within p-value is derived from paired t-test. ** Between p-value is derived from ANCOVA. *** Dose Response p-value is derived from the contrasts of the least-square means from ANCOVA model. ANCOVA model: change = baseline + treatment Linear Contrast Quadratic Contrast Abbreviations: ATMX = atomoxetine; n = number of patients; SD = standard deviation. CT Registry ID# 5285 Page 28
29 CT Registry ID# 5285 Page 29 Table LYBC.12 summarizes the categorical analysis results of changes in blood pressure (systolic and diastolic), heart rate (pulse), and weight for atomoxetine- and placebotreated patients. For each criterion the percentage of patients meeting the criteria in a treatment-emergent manner (at any Study Period II visit) was computed for each treatment group. With the exception of systolic and diastolic blood pressure, all trends were statistically significant (p<0.05). Increased heart rate (pulse) was not unexpected due to atomoxetine s noradrenergic mechanism of action.
30 Table LYBC.12. Summary of Vital Signs Data Analysis of Categorical Changes in Blood Pressure, Heart Rate(Pulse) and Weight Patients Who Took at Least 1 Dose of Study Medication Placebo ATMX 0.5 ATMX 1.2 ATMX 1.8 ATMX all p-value (N=62) (N=62) (N=60) (N=61) (N=183) CA Trend Criteria. N n (%) N n (%) N n (%) N n (%) N n (%) Test* A B C D <0.001 E F Criteria: A: Maximum heart rate (Pulse)Visits 3-6 of >=110bpm B: Change to Maximum Heart rate (Pulse) of >= 25 bpm C: A and B D: Weight Loss from baseline to endpoint of >= 3.5% E: Sitting Max. Systolic BP of >= Hypertension Assessment Criteria F: Sitting Max. Diastolic BP of >= Hypertension Assessment Criteria *p-value is derived from Cochran Armitage Trend test. Abbreviations: ATMX = atomoxetine; N = number of patients; n = number of patients meeting the criteria; TEAE = treatment-emergent adverse event. CT Registry ID# 5285 Page 30
31 CT Registry ID# 5285 Page 31 Electrocardiograms Summaries of the mean change from baseline to LOCF endpoint in electrocardiogram (ECG) intervals and heart rate are shown in Table LYBC.13. Mean increases in heart rate were observed for all atomoxetine treatment groups compared with placebo. These leveled off at atomoxetine 1.2 mg/kg/day, but all increases were statistically significant (p<0.05). Differences between treatment groups were also statistically significant (p<0.001). Relative to placebo, all doses of atomoxetine were also associated with mean decreases in QT interval. On the other hand, the Bazett correction for QT interval, showed a statistically significant (p<0.05) prolongation of the mean QTc interval for each atomoxetine treatment group. However, for drugs associated with increased heart rate, the Bazett correction is known to over-correct for heart rate effects. In this case the Fridericia or Data Driven correction is more appropriate. Analyses of the ECG results using the Fridericia correction showed a mean decrease in QT interval for the atomoxetine 1.2 mg/kg/day and 1.8 mg/kg/day groups. A 2.07 msec prolongation was still seen in the atomoxetine 0.5 mg/kg/day group, but this was less than half of that seen with the Bazett correction. Data driven correction resulted in mean increases of QTc interval for all atomoxetine treatment groups, but none of the observed increases were found to be statistically significant, either with the Data Driven or Fridericia correction. All mean increases seen with either of these two QT interval corrections were below 5 msec. Also, unlike the Bazett correction, neither the Fridericia nor the Data Driven correction gave any evidence of a statistically significant linear dose response. Table LYBC.14 summarizes categorical changes in QTc intervals using Food and Drug Administration (FDA) criteria. Even though statistically significant trends were observed for criterion D (increase from baseline 30 msec) for both the Fridericia (p=0.015) and Data Driven (p=0.034) corrected QTc intervals, no cases were reported for a QTc interval >450 msec (criteria A, B, C), nor were any cases reported for a QTc increase from baseline 60 msec (criteria E). The number of patients in the atomoxetine treatment groups with QTc prolongation between 30 msec and 60 msec seen with both correction methods were: Fridericia (8.2% : 15/183), Data Driven (8.7% : 16/183). No serious adverse events due to QTc interval prolongation were reported during the study.
32 Table LYBC.13. Electrocardiograms Mean Change from Baseline to LOCF Endpoint Patients Who Took at Least 1 Dose of Study Medication Baseline Endpoint Change p-value Therapy n Mean SD Mean SD Mean SD Within* Between** Heart Rate Placebo <0.001 ATMX ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.011 RR Interval Placebo <0.001 ATMX ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.003 PR Interval Placebo ATMX ATMX ATMX Dose Response*** Linear: P=0.375 Quadratic: P=0.732 CT Registry ID# 5285 Page 32
33 Table LYBC.13. Electrocardiograms Mean Change from Baseline to LOCF Endpoint Patients Who Took at Least 1 Dose of Study Medication (Continued) Baseline Endpoint Change p-value Therapy n Mean SD Mean SD Mean SD Within* Between** QRS Interval Placebo ATMX ATMX ATMX Dose Response*** Linear: P=0.142 Quadratic: P=0.574 QT Interval Placebo <0.001 ATMX ATMX <0.001 ATMX <0.001 Dose Response*** Linear: P=<0.001 Quadratic: P=0.017 Corrected Placebo QT Interval ATMX (Bazett) ATMX ATMX Dose Response*** Linear: P=0.002 Quadratic: P=0.173 CT Registry ID# 5285 Page 33
Summary ID# Clinical Study Summary: Study B4Z-JE-LYBD
CT Registry ID#5286 Page 1 Summary ID# 5286 Clinical Study Summary: Study B4Z-JE-LYBD An Open Label, Dose-Titration Safety Study of Hydrochloride in Outpatient Japanese Children with Attention-Deficit/Hyperactivity
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBR
CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate
More informationSummary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ
CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYAX
CT Registry ID#5004 Page 1 Summary ID# 5004 Clinical Study Summary: Study B4Z-MC-LYAX A Randomized, Double-Blind, Placebo-Controlled Study of Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity
More informationSummary ID#2552. Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV)
CT Registry ID# 2552 Page 1 Summary ID#2552 Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV) Relapse Prevention after 10-Week and 52-Week Treatment
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationSummary ID# Clinical Study Summary: Study B4Z-SB-LYDD
CT Registry ID# 9496 Page 1 Summary ID# 9496 Clinical Study Summary: Study B4Z-SB-LYDD An Open-label Study on Effectiveness and Tolerability of as Perceived by Patients, Parents, and Physicians in Children
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More information(b) (4) B. Recommendation on Phase 4 Studies and/or Risk Management Steps
1 REVIEW AND EVALUATION OF CLINCIAL DATA NDA 20-822 (b) (4) 016 Sponsor: Forest Labs Drug: Celexa. (citalopram hydrocloride) Material Submitted: Pediatric Supplement (b) (4) 016 Date Submitted: 4/18/02
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Effexor XR /
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSummary ID# Clinical Study Summary: Study F1J-MC-HMDV
CT Registry ID# 7108 Page 1 Summary ID# 7108 Clinical Study Summary: Study F1J-MC-HMDV Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationJeffrey H. Newcorn 1 Peter Nagy. Brian Yan 5 Steven Pliszka
CNS Drugs DOI 10.1007/s40263-017-0468-2 ORIGINAL RESEARCH ARTICLE Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Not approved yet for any
More informationRole of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationIRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationSummary ID# Clinical Study Summary: Study B4Z-US-LYBH
CT Registry ID# 5671 Page 1 Summary ID# 5671 Clinical Study Summary: Study B4Z-US-LYBH Placebo-Controlled Study of the Effects of Atomoxetine Hydrochloride on Bladder Control in Children with Nocturnal
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: Not Applicable
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended.
Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Atomoxetine Strattera UK/W/010/pdWS/005 Rapporteur: UK Finalisation procedure
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : FEXOFENADINE Study number : PJPR0024 Study title : A double-blind, randomized, placebo-controlled, parallel study comparing the efficacy and safety of three dosage strengths of MDL 16,455A
More informationAbstract and Introduction
Increasingly physicians are using Atomoxetine known as Strattera as the only non-stimulant for the treatment of ADHD. Since ADHD is the most frequently diagnosed psychological disorder in children and
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More information